Our pipeline of products in development includes the following lead compounds: PH94B nasal spray for acute treatment of social anxiety disorder and PH10 nasal spray for acute, intermittent, and long-term treatment of depression, both recently licensed to VistaGen Therapeutics; PH80-HF nasal spray for acute and long-term management of menopausal hot flashes and other symptoms of menopause; PH15 nasal spray for cognitive improvement; and PH284 for increasing appetite in anorexic patients. We are open to discussions of collaborative licensing opportunities with forward-looking and technologically innovative pharmaceutical companies.
A Phase 2A was successfully completed using PH80-HF nasal spray for the acute management of menopausal hot flashes. Results show relief of the number and severity of menopausal hot flashes significantly better from the effect of placebo. Also completed is a Phase 2B clinical efficacy and safety study of PH80-PMD nasal spray for acute and intermittent treatment of premenstrual distress. PH80-PMD administered intranasally PRN decreased moderate and severe premenstrual symptoms significantly better than placebo during the critical premenstruals days of the cycle without the need of chronic administration.
A Phase 2A study using PH284 nasal spray in 40 inpatients with anorexia due to terminal disease was conducted by Pherin Pharmaceuticals. Results show rapid increase of the subjective feeling of hunger, increased body weight at the end of the treatment period, and increased quality of life significantly better than the effect of placebo.
Numerous Therapeutic Advantages
The direct neural connections of nasal receptor cells to the chemosensory system and hypothalamus and the ability of our compounds to act intranasally and locally, pherines do not need to achieve systemic absorption and distribution. This provides a significant therapeutic advantage over traditional therapeutics targeted at the central nervous system that requires access to the systemic circulation and must cross the blood-brain barrier, followed by uptake into the brain to exert their therapeutic effects.